Next Generation Sequencing (NGS) is a platform that enabled the sequencing of thousands to millions DNA molecules simultaneously. It is also known as the massively parallel sequencing technology. This sequencing helps in the various fields such as personalized medicine, clinical diagnostics, and genetic diseases due to its capability to sequence multiple individuals at the same time.              

Market Dynamics

Continuous technological innovations in next generation sequencing platforms and software is responsible for the entry of efficient, effective, easy to use, and portable products in the market. Significant investment in R&D by market players leads to availability of platforms that provide accurate and faster results. The advancement in the bioinformatics area also enhances the adoption of NGS technology in diagnosis and analysis of rare diseases, for prenatal testing, and identifying therapeutic targets.

Significant decline in the cost of NGS to USD 1,000 - 1200 per genome in 2017 from USD 95.26 million in 2001 and USD 108.1 thousand in 2009 will boost the market growth. This reduction of cost is majorly attributed to the significant decline in the installation cost of sequencing platforms. This is also anticipated to have a positive impact on the demand for NGS techniques. Development, approvals, and commercialization of innovative products and services by key market players is also expected to propel the growth. For instance, in January 2018, Illumina launched iSeq 100 Sequencing System. This new, NGS system provides high accuracy at low capital cost and hence making this technology available at any lab.

Product & Services Stance

Based on the product & services, the market has been segmented into NGS platforms & related products and NGS services. In 2018, platforms and related products accounted for the largest share of the market. Related products include software and instruments used during sample preparation and sequencing of those samples. Major players operating in the NGS platform market are Illumina, Thermo Fisher Scientific, Pacific Biosciences, and Oxford Nanopore Technologies. However, NGS services market is anticipated to grow at the fastest rate during the forecast period. These services help the scientist to better understand genomic sequences in the diagnosis of chronic and rare diseases, such as cancer.   

Application Overview

Based on application, the NGS market is divided into oncology, reproductive health, clinical investigation, immune system monitoring, agriculture & animal research, epidemiology & drug development, and consumer genomics. Oncology held the maximum share of the market in 2018. High research in the field and lesser availability of alternative treatments are the key reasons for the dominance in the market.

Technology Overview

Based on the technology, the market has been segmented into whole genome sequencing, targeted sequencing & resequencing, and whole exome sequencing. In 2018, targeted sequencing and resequencing accounted for the largest share of the market due to its ability of rapid and cost-effective detection of known variants in selected genes. However, demand for the whole genome sequencing is anticipated to increase with the fastest rate during the forecast period.

End-User Study

On the basis of end user, the NGS market is subsegmented into academic institutes & research centers, hospitals & clinics, pharmaceutical & biotechnology companies, and other users. Academic institutes & research centers held the maximum share of the market in 2018 due to wide application of NGS in Ph.D projects and research. Furthermore, the segment anticipated to observe the fastest growth as well owing to strong clinical pipeline. 

Geographically Analysis

Geographically, the North America region dominated in the next generation sequencing market in 2018 and is expected to maintain its share during the forecast period. This can be attributed to high investment in research and development activities, local presence of major market players, more awareness about new technologies, and increasing prevalence of infectious diseases and cancer. However, the Asia Pacific region is anticipated to propel the market growth at the fastest rate during the forecast period. This is due to growing investment by pharmaceutical and biotechnology companies considering high growth in the region and funding provided by the private and government organization for the development of innovative and effective treatment. Additionally, presence of large pool of targeted patients increases the demand for next generation sequencing from the region.      

The market research study on “Next Generation Sequencing Market – Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 – 2026”, offers a detailed insight on the global next generation sequencing market entailing insights on its different market segments. Market dynamics with drivers, restraints, and opportunities with their impact are provided in the report. The report provides insights into the global next generation sequencing market, its products & services, technology, its application, its end users,  and major geographic regions. The report covers basic development policies and layouts of technology development processes. Secondly, the report covers global next generation sequencing market size and segment markets by products & services, by technology, by application, by end users, and geography along with the information on companies operating in the market. The next generation sequencing market analysis is provided for major regional markets including North America, Europe, Asia Pacific, Latin America and Middle East and Africa. For each region, the market sizes for different segments have been covered under the scope of the report.   

The players profiled in the report include BGI, Bio-Rad Laboratories, Inc., DNASTAR, Inc., Eurofins GATC Biotech GmbH; F Hoffman-La Roche Ltd., Genomatix GmbH, Illumina Inc.; Oxford Nanopore Technologies, Perkin Elmer, Inc., PierianDx, Inc., QIAGEN, and Thermo Fisher Scientific, Inc. Market players are adopting strategic moves such as collaboration for development and geographical expansion in the untapped region.  

Market Segmentation

By Products and Services

• NGS Platforms & Related Products
• NGS Services

By Application

• Oncology
• Reproductive Health
• Clinical Investigation
• Immune System Monitoring
• Agriculture & Animal Research
• Epidemiology & Drug Development
• Consumer Genomics

By Technology

• Whole Genome Sequencing
• Targeted Sequencing & Resequencing
• Whole Exome Sequencing

By End Users

• Academic Institutes & Research Centers
• Hospitals & Clinics
• Pharmaceutical & Biotechnology Companies
• Other users

By Geography

• North America
  • US
  • Canada
• Europe
  • UK
  • Germany
  • France
  • Spain
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa